Structured evidence table for Barley Blood Glucose Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Barley Blood Glucose Meta-Analysis | Chronic diseases, characterized by their high prevalence and protracted course, represent a paramount challenge to global public health, necessitating effective, evidence-based preventive strategies. | 3 | Zhang X (2025) | From Broad-Spectrum Health to Targeted Prevention: A Review of Functional Foods in Chronic Disease Management. |
| Barley Blood Glucose Meta-Analysis | This review bridges this critical gap by systematically evaluating the scientific evidence and application potential of functional foods, with a specific focus on key bioactive compounds-β-glucan, omega-3 polyunsaturated fatty acids (PUFAs), dietary fiber, and catechins. | 3 | Zhang X (2025) | From Broad-Spectrum Health to Targeted Prevention: A Review of Functional Foods in Chronic Disease Management. |
| Barley Blood Glucose Meta-Analysis | Our unique contribution lies in integrating the ancient wisdom of food-medicine homology with modern multi-omics and evidence-based research, thereby proposing a refined nutritional intervention paradigm. | 3 | Zhang X (2025) | From Broad-Spectrum Health to Targeted Prevention: A Review of Functional Foods in Chronic Disease Management. |
| Barley Blood Glucose Meta-Analysis | While functional foods are widely recognized for their potential, a comprehensive synthesis elucidating their multitargeted mechanisms within a "food-medicine homology" framework and a clear trajectory from broad-spectrum health promotion to targeted intervention remains lacking. | 3 | Zhang X (2025) | From Broad-Spectrum Health to Targeted Prevention: A Review of Functional Foods in Chronic Disease Management. |
| Barley Blood Glucose Meta-Analysis | In weighing the evidence, the Panel considered that the human intervention studies did not consistently show a significant effect of beta-glucans from oats or barley on postprandial glucose iAUC at doses between 2 and < 4 g BG/30 g avCHO, and that dose-response data suggest a lowest effective dose above the 2 g/30 g avCHO proposed by the applicant. | 4 | EFSA Panel on Nutrition (2025) | Beta-glucans from oats or barley and reduction of postprandial glycaemic responses: Modification of an authorised health claim pursuant to Article 13(1) of Regulation (EC) No 1924/2006 following a request in accordance with Article 19 of Regulation (EC) No 1924/2006. |
| Barley Blood Glucose Meta-Analysis | Following an application from PepsiCo International, submitted pursuant to Article 19 of Regulation (EC) No 1924/2006 via the Competent Authority of Ireland, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the modification of an authorised health claim related to beta-glucans from oats or barley and reduction of postprandial glycaemic responses. | 4 | EFSA Panel on Nutrition (2025) | Beta-glucans from oats or barley and reduction of postprandial glycaemic responses: Modification of an authorised health claim pursuant to Article 13(1) of Regulation (EC) No 1924/2006 following a request in accordance with Article 19 of Regulation (EC) No 1924/2006. |
| Barley Blood Glucose Meta-Analysis | The proposed modification concerns a reduction of the lowest effective dose from 4 g to 2 g of beta-glucans (BG) per 30 g of available carbohydrates (avCHO). | 4 | EFSA Panel on Nutrition (2025) | Beta-glucans from oats or barley and reduction of postprandial glycaemic responses: Modification of an authorised health claim pursuant to Article 13(1) of Regulation (EC) No 1924/2006 following a request in accordance with Article 19 of Regulation (EC) No 1924/2006. |
Source documents